White Button Mushroom, Agaricus bisporus (Agaricomycetes), and a Probiotics Mixture Supplementation Correct Dyslipidemia without Influencing the Colon Microbiome Profile in Hypercholesterolemic Rats.

Consumption of foods rich in dietary fiber has attracted considerable attention for lowering blood cholesterol and triglycerides through attenuation of gut microbiome. Diets rich in fiber may provide substrates for microbes to digest and proliferate. In response, products of microbial digestion enter systemic circulation and support host energy homeostasis. In the present study, rats with hypercholesterolemia (HC) were supplemented with probiotics (PB) and Agaricus bisporus mushroom to examine the antidyslipidemia effects. Forty adult rats were divided into five treatment groups. The rats in the control group were fed only a chow maintenance diet (CON; n = 8), whereas an atherogenic diet (chow diet supplemented with 1.5% cholesterol and 0.5% cholic acid) was offered to the remaining rats to induce hypercholesterolemia (HC group; n = 32). Rats developed HC following a 24-day continuous supplementation with the atherogenic diet. From day 25 onward, the HC group was further divided into HC-CON, HC-PB (supplemented with PB at 1 mg/rat/day), HC-AB (supplemented with A. bisporus at 5% of diet), and HC-AB.PB (supplemented with both A. bisporus and PB). After 6 weeks of supplementation, rats were killed to collect blood to determine serum lipid profile, oxidative stress, and for metagenomics analysis of colon contents. Results showed that all supplementations corrected HC-induced oxidative stress. Furthermore, A. bisporus supplementation corrected HC-induced dyslipidemia (P ≤ .05). Blautia and Bifidobacterium were the most dominant bacterial genera in HC-AB and HC-PB groups, respectively. Phylum Firmicutes and class Clostridia predominantly occupied the gut microbiome in all groups. However, no significant differences were observed in microbiome diversity and clustering patterns among study groups. In conclusion, supplementation of A. bisporus mushroom and probiotics can lower oxidative stress and dyslipidemia with partial effects on the phylogenetic makeup in the gut microbiome.

Ex-vivo antihypertensive and calcium channel blocking activity of Androsace foliosa n-hexane leaves fraction on isolated rabbit aorta.

Hypertension is persistent elevation in blood pressure for 3-4 weeks. Estimated global prevalence of hypertension suggested that by the Year 2025 (29%) of adult worldwide are suffering from hypertension (1.56 billion). Hypertension complications are hemorrhage, atherosclerosis, renal artery stenosis, angina pectoris end organ damage, cardiomyopathy, myocardial infarction and retinopathy. Along with other drug class Calcium channel blocker are also used for the treatment of hypertension. In this study the possible action of the n-hexane leaves fraction of the Androsace foliosa on isolated rabbit aorta was examined. Antihypertensive activity was examined in the existence of standard agonist like phenylephrine and antagonist like Verapamil. Phenylephrine (PE 1µM) high K+ was used to steady the tissue materials. Additionally to observe the calcium channel blocking effect the tissues were treated with n-hexane segment of A. foliosa leaves. Aortic tissues were treated 4-5intervals with Ca+2- free preparation earlier to control calcium reaction curve (CRCs). Verapamil is utilized as standard calcium channel inhibitory mediator and is used as an antagonist. The Af. n-hexane leaves fraction completely inhibited the precontractions induced by Phenylephrine (1µM) and K+ (80 mM) precontractions, with EC50 standards of 1.0mM (0.3-1.0mg/mL) and 4.90mM (1-3mg/mL), respectively. Androsace foliosa n-hexane leaves fraction was tested for calcium channel inhibitory effect on isolated rabbit aorta. A. foliosa n- hexane leaves segment at the dosage of 1mg/mL block the calcium channel approximately (35±5%). Consequence indicates that A. foliosa n-hexane leaves segment block calcium channel in the similar manner as compared to the standard calcium channel blocker drug (verapamil).